Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q2 FY26
Bearish
6
Neutral
5
Bullish
3
Bearish
14
Neutral
9
Bullish
23
Bearish
8
Neutral
4
Bullish
20
Discovery themes featuring this stock
Accretion Pharmaceuticals Limited specializes in manufacturing and marketing high-quality generic and branded pharmaceutical formulations. They listed on the NSE Emerge platform in May 2025 and achieved a 40% production capacity increase post-IPO.
The company recorded a remarkable revenue growth of 135.59% in H1 FY '26, driven by a diversified product mix and strategic market expansion.
Accretion focuses on expanding its reach into high-growth markets like Africa, Southeast Asia, and Latin America, leveraging certifications like WHO-cGMP and ISO 9001-2015.
The executive team emphasizes a robust export strategy, with over 100 products under registration across multiple countries, highlighting their aggressive market penetration efforts.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
76 Cr
Low Risk
8.4
28.4
0.0
1.7
102.50
53.80
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Accretion Pharmaceuticals Ltd (ACCPL) is currently trading at 70.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Accretion Pharmaceuticals Limited specializes in manufacturing and marketing high-quality generic and branded pharmaceutical formulations. They listed on the NSE Emerge platform in May 2025 and achieved a 40% production capacity increase post-IPO. The company recorded a remarkable revenue growth of 135.59% in H1 FY '26, driven by a diversified product mix and strategic market expansion. Accretion focuses on expanding its reach into high-growth markets like Africa, Southeast Asia, and Latin America, leveraging certifications like WHO-cGMP and ISO 9001-2015. The executive team emphasizes a robust export strategy, with over 100 products under registration across multiple countries, highlighting their aggressive market penetration efforts.
Over the past 52 weeks, Accretion Pharmaceuticals Ltd has traded between a low of ₹53.80 and a high of ₹102.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Accretion Pharmaceuticals Ltd has a market capitalization of approximately 75.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Accretion Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.37 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 75.64 Cr, Accretion Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Accretion Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Accretion Pharmaceuticals Ltd is 8.37. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6.62 | 89 Cr | -2.34 | 1.31 | 0.00 | -0.57 | 1.54 | -0.43 | |
96.20 | 81 Cr | 9.35 | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 | |
128.00 | 80 Cr | 29.63 | 3.36 | 0.00 | 12.56 | 15.10 | 6.85 | |
70.95 | 76 Cr | 8.37 | 1.68 | 0.00 | 19.50 | 25.71 | 15.37 | |
72.00 | 75 Cr | 141.18 | 2.18 | 0.00 | 1.67 | 6.00 | 0.83 | |
33.40 | 67 Cr | 5.04 | 0.97 | 0.00 | 11.07 | 11.52 | 10.35 | |
32.60 | 61 Cr | 9.85 | 1.10 | 0.00 | 1.95 | 4.14 | 1.16 |
